Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2008

View Archived Issues

Positive results emerge from phase III ALO-01 study in patients with osteoarthritis pain

rhEPO shows clinical benefits for the treatment of amyotrophic lateral sclerosis

Cenomed reports on new schizophrenia and posttraumatic stress disorder candidates

Mutation-specific effects seen with pyrimethamine in familial ALS patients

Novel means of avoiding opioid-related adverse events reported in recent Progenics patent

Recent GenkyoTex patent imparts novel therapeutics for cardiovascular disorders

New antiinflammatory agents reported in recent Biolipox patents

Alizyme presents update on clinical development activities between July and November 2008

FDA reschedules Advisory Committee meeting with Novo for liraglutide until April 2009

Memory completes enrollment in phase II trial of MEM-3454 in CI associated with schizophrenia

CytRx updates progress of third quarter 2008

Chelsea Therapeutics completes enrollment in phase II trial of droxidopa in IDH

GenVec reports interim results from phase III PACT trial of TNFerade

Phase III studies show vandetanib offers benefit to patients with lung cancer

BioDelivery Sciences to resubmit REMS for Onsolis to FDA in December 2008

Karo Bio and Wyeth extend drug discovery collaboration with LXR in inflammatory diseases

BI-201335 well tolerated, active in treatment-naive and -experienced HCV patients

Hyperphosphatemia controlled with fermagate in hemodialysis patients

Elixir's reports results from phase III trial of metformin-mitiglinide therapy

Telavancin receives favorable recommendation from FDA

Cougar Biotechnology commences phase I/II CB-7630 trial in breast cancer

Ortho Biotech submits NDA for trabectedin for relapsed ovarian cancer

Debiopharm and Aurigene sign licensing agreement for Debio-0617

Grazax approved in Europe for children with hay fever

Basilea's Zevtera receives positive opinion from the CHMP

GlaxoSmithKline receives FDA accelerated approval for Promacta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...